Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of TPF induction chemotherapy followed by hyperfractionated radiotherapy plus cetuximab versus radiotherapy plus cetuximab in HPV-positive unresectable head and neck squamous cell carcinoma
2009-013438-26Phase 2Completed
- Sponsor
- Karolinska University Hospital
- Start
- Jul 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, cisplatin, fluorouracil and cetuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Progression-free survival. Started Jul 2010; status: completed.
02
Drugs
docetaxelcisplatinfluorouracilcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2009-013438-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013438-26.